Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 20/20 | 1.00 |
| ▸ | HTR2A | P28223 | 15/20 | 0.86 |
| ▸ | HTR2B | P41595 | 9/20 | 0.86 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.78 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.78 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.78 |
| ▸ | DRD3 | P35462 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4024803 | 0.99 | HTR2C (0.98) | HTR2CHTR2AHTR2BADRA1DADRA1A | |
| SCHEMBL4031012 | 0.91 | HTR2C (1.00) | HTR2CHTR2AHTR2BADRA1DADRA1A | |
| Hydrochloric Acid SCHEMBL4028501 | 0.91 | HTR2C (0.98) | HTR2CHTR2AHTR2BADRA1DADRA1A | |
| SCHEMBL4025461 | 0.90 | HTR2C (1.00) | HTR2CHTR2AHTR2BADRA1DADRA1A | |
| Hydrochloric Acid SCHEMBL4025820 | 0.89 | HTR2C (0.98) | HTR2CHTR2AHTR2BADRA1DADRA1A | |
| SCHEMBL4021654 | 0.88 | HTR2C (1.00) | HTR2CHTR2AHTR2BADRA1DADRA1A | |
| SCHEMBL4026106 | 0.87 | HTR2C (1.00) | HTR2CHTR2AHTR2BADRA1DADRA1A | |
| SCHEMBL4623543 | 0.87 | HTR2C (1.00) | HTR2CHTR2AHTR2BADRA1DADRA1A | |
| SCHEMBL4623347 | 0.87 | HTR2C (1.00) | HTR2CHTR2AHTR2BADRA1DADRA1A | |
| SCHEMBL4622795 | 0.86 | HTR2C (1.00) | HTR2CHTR2AHTR2BADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1497265-B1 | COMPOUNDS HAVING AFFINITY AT 5HT2C RECEPTOR AND USE THEREOF IN THERAPY | GLAXO GROUP LTD (GB) | 2009-02-18 | — | — | EP | claimed |
| US-20050203079-A1 | Compounds having affinity at 5ht2C receptor and use thereof in therapy | GLAXO GROUP LIMITED | 2005-09-15 | — | — | US | claimed |
| EP-1497265-B1 | COMPOUNDS HAVING AFFINITY AT 5HT2C RECEPTOR AND USE THEREOF IN THERAPY | GLAXO GROUP LTD (GB) | 2009-02-18 | — | — | EP | disclosed |
| US-20050203079-A1 | Compounds having affinity at 5ht2C receptor and use thereof in therapy | GLAXO GROUP LIMITED | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203079-A1 | Compounds having affinity at 5ht2C receptor and use thereof in therapy | HTR7, HTR2C, HTR3C | HTR2C 2/4885HTR2A 17/4885HTR2B 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.